Information Provided By:
Fly News Breaks for June 13, 2019
CNCE
Jun 13, 2019 | 07:11 EDT
H.C. Wainwright analyst Andrew Fein raised his price target for Concert Pharmaceuticals to $29 from $26 saying the safety data of CTP-692 "cleared a major hurdle." The analyst believes a sizable portion of the development risk for CTP-692 is related to safety and dose in clinical trials. As such, the Phase 1 results reported yesterday "cleared a major roadblock, and significantly de-risked the molecule risk," Fein tells investors in a research note. He reiterates a Buy rating on Concert Pharmaceuticals.
News For CNCE From the Last 2 Days
There are no results for your query CNCE